siguazodan

{{Chembox

| ImageFile = Siguazodan.svg

| ImageSize = 200px

| ImageAlt =

| IUPACName = 1-Cyano-2-methyl-3-[4-(4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl)phenyl]guanidine

| OtherNames =

|Section1={{Chembox Identifiers

| CASNo = 115344-47-3

| CASNo_Ref = {{Cascite|changed|CAS}}

| ChEBI = 91791

| ChEMBL = 1256712

| ChemSpiderID = 65101

| EINECS = 634-221-4

| PubChem = 72124

| UNII = 5E4UI00UQJ

| InChI=1S/C14H16N6O/c1-9-7-12(21)19-20-13(9)10-3-5-11(6-4-10)18-14(16-2)17-8-15/h3-6,9H,7H2,1-2H3,(H,19,21)(H2,16,17,18)

| InChIKey= NUHPODZZKHQQET-UHFFFAOYSA-N

| SMILES =CC1CC(=O)NN=C1C2=CC=C(C=C2)NC(=NC)NC#N }}

|Section2={{Chembox Properties

| C=14 | H=16 | N=6 | O=1

| Appearance =

| Density =

| MeltingPt =

| BoilingPt =

| Solubility = }}

|Section3={{Chembox Hazards

| MainHazards =

| FlashPt =

| AutoignitionPt = }}

}}

Siguazodan is a phosphodiesterase inhibitor.{{cite journal|pmid=18788505|year=2008|last1=Sosroseno|first1=W|last2=Sugiatno|first2=E|title=Cyclic-AMP-dependent proliferation of a human osteoblast cell line (HOS cells) induced by hydroxyapatite: Effect of exogenous nitric oxide|volume=79|issue=2|pages=110–6|journal=Acta Biomedica }}